Clinical trials such as PACE have demonstrated prolonged mPFS and overall survival in patients with HR+/HER2- BC when combining palbociclib with endocrine therapy and avelumab (anti-PD-L1) compared to fulvestrant alone [77]. The gene discussed is ERBB2; the disease is breast cancer.